Allogeneic haematopoietic cell transplant in patients with relapsed/refractory anaplastic large cell lymphoma

• Published in: British journal of haematology 2023-01, Vol.200 (1), p.54-63
• Main Authors: Furqan, Fateeha, Ahn, Kwang W., Chen, Yue, Kaur, Manmeet, Abutalib, Syed A., Ahmed, Nausheen, Ahmed, Sairah, Kharfan‐Dabaja, Mohamed A., Friedberg, Johnathan, Gregory, Tara, Hill, LaQuisa, Sterling, Cole, Barta, Stephan K., Shadman, Mazyar, Perales, Miguel‐Angel, Zain, Jasmine, Herrera, Alex F., Sauter, Craig, Hamadani, Mehdi
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; allogeneic transplantation; Anaplastic large-cell lymphoma; Chronic Disease; Disease control; graft versus leukaemia; Graft vs Host Disease - etiology; graft‐versus‐host disease; Hematology; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Lymphoma, Large-Cell, Anaplastic - therapy; Medical prognosis; Neoplasm Recurrence, Local; Prognosis; Progression-Free Survival; Race; Retrospective Studies; Transplantation; Transplantation Conditioning; Transplants & implants
• ISSN: 0007-1048; 1365-2141
• DOI: 10.1111/bjh.18467

Summary The prognosis of relapsed/refractory (R/R) anaplastic large cell lymphoma (ALCL) is poor. Large studies evaluating outcomes of allogeneic haematopoietic cell transplantation (allo‐HCT) in systemic R/R ALCL are not available. Using the Center for International Blood and Marrow Transplant Research (CIBMTR) database, we evaluated outcomes of 182 adults (aged ≥18 years) with R/R ALCL undergoing allo‐HCT between 2008 and 2019. Non‐relapse mortality (NRM), disease relapse/progression (REL), progression‐free survival (PFS), and overall survival (OS) were modelled using Cox proportional hazards models. The median (range) follow‐up of survivors was 62 (3–148) months. The 1‐year NRM was 18%. The 5‐year REL, PFS and OS were 32%, 41% and 56% respectively. On multivariable regression analysis African American race (hazard ratio [HR] 2.7, 95% confidence interval [CI] 1.6–4.8; p